Skip to main content

    From predictions to the wet lab

    Translating in-silico predictions into wet lab experiments, from hit prioritization through lead optimization and CRO engagement.

    nextstepswetlab-product-roadmap

    The platform produces ranked compound lists, predicted binding poses, ADMET profiles, and synthesis routes. This page outlines how to convert those computational outputs into an experimental validation plan -- from cherry-picking hits for synthesis through dose-response screening, lead optimization, and eventually IND-enabling studies.

    This guide describes a general small-molecule workflow. Biologics (antibodies, peptides, oligonucleotides) follow a parallel path with different assay types but the same prioritization logic.


    From analysis to wetlab execution

    The computational-to-experimental gap

    In-silico predictions are hypotheses, not facts. Every docking score, ADMET prediction, and de novo design must be validated experimentally before it can inform a drug program. The goal of this roadmap is to minimize wasted synthesis and assay cycles by applying rigorous triage criteria to computational outputs before committing wet lab resources.

    Workflow overview

    .bloom* Computational Results
      |
      v
    Hit Triage & Prioritization
      |
      v
    Compound Procurement / Synthesis
      |
      v
    Primary Screening (binding, activity)
      |
      v
    Dose-Response & Selectivity
      |
      v
    ADMET Confirmation (in vitro)
      |
      v
    Lead Optimization Cycle
      |
      v
    In Vivo PK / Efficacy
      |
      v
    IND-Enabling Studies

    Planning experimental validation

    Define success criteria up front

    Before synthesizing or purchasing any compounds, agree on quantitative go/no-go thresholds:

    ParameterTypical thresholdNotes
    Biochemical IC50< 1 uMDepends on target class
    Cell-based EC50< 10 uMCounter-screen for cytotoxicity
    Selectivity ratio> 30x over closest homologCritical for kinases, GPCRs
    Aqueous solubility> 10 ug/mLMinimum for in vitro assays
    Microsomal stabilityt1/2 > 30 min (human)Enables oral dosing
    hERG IC50> 10 uMSafety margin for cardiac liability

    Experimental design considerations

    • Positive and negative controls: Include known active and inactive compounds in every assay plate. The platform's compound passport reports literature-sourced reference values that can guide control selection.
    • Replicate strategy: Run a minimum of 3 biological replicates for dose-response curves. Technical triplicates are standard for single- point screens.
    • Blinding: Where possible, blind the experimentalist to computational predictions to avoid confirmation bias in data interpretation.

    Prioritizing computational hits for synthesis

    Triage criteria

    Apply filters to the platform export in order of cost:

    1. Structural alerts -- Remove compounds flagged as PAINS, reactive metabolites, or DNA-intercalating. The platform's ADMET tools flag these automatically.
    2. Predicted ADMET -- Exclude compounds with predicted poor solubility (< 1 ug/mL), high CYP inhibition risk, or hERG liability. Use the platform's ADMET-AI outputs.
    3. Synthetic accessibility -- Prioritize compounds with a synthetic accessibility (SA) score below about 4 on the 1-10 Ertl-Schuffenhauer scale, and with a solved AiZynthFinder route. Higher SA scores and unsolved routes point to multi-step or low-yielding chemistry that raises cost and delays timelines.
    4. Chemical diversity -- Cluster remaining hits by Tanimoto similarity (ECFP4, cutoff 0.4) and select 1-2 representatives per cluster. This maximizes SAR information per dollar spent.
    5. Docking pose quality -- For structure-based campaigns, inspect the top docking poses in the platform's 3D viewer. Discard compounds where the predicted binding mode places key pharmacophoric groups in solvent rather than in the binding pocket.

    Procurement vs. custom synthesis

    SourceTurnaroundCost per compoundWhen to use
    Commercial vendors (e.g. Enamine, Mcule)1-3 weeks$50-$300Hit validation, SAR exploration
    Make-on-demand (Enamine REAL)3-6 weeks$300-$1,000Near-analogs not in stock
    Custom CRO synthesis6-12 weeks$2,000-$10,000+Lead optimization, novel scaffolds

    Start with commercially available analogs to validate the scaffold before investing in custom synthesis. The platform's AiZynthFinder routes flag whether each building block is in its stock set (a ZINC in-stock snapshot); confirm current price and availability with the vendor before ordering.


    Primary screening

    Binding assays

    • SPR (Surface Plasmon Resonance): Measures real-time binding kinetics (kon, koff, KD). Best for confirming predicted binding and ranking hits by affinity.
    • TSA (Thermal Shift Assay): A low-cost, high-throughput screen. Compounds that stabilize the target protein shift its melting temperature (delta-Tm > 1C is a positive hit).
    • FP (Fluorescence Polarization): Competitive binding assay useful when a fluorescent probe ligand is available.

    Activity assays

    • Enzymatic assays: For enzyme targets, measure substrate turnover in the presence of compound. IC50 determination requires an 8-point dilution series.
    • Cell-based reporters: For intracellular targets, use reporter gene assays (luciferase, GFP) to measure pathway modulation.

    Dose-response and selectivity screening

    Dose-response curves

    Confirmed hits from primary screening advance to full dose-response characterization:

    1. Concentration range: Test 8-10 half-log dilutions spanning 4-5 orders of magnitude (e.g., 100 uM to 1 nM).
    2. Curve fitting: Fit data to a four-parameter logistic (4PL) model to derive IC50/EC50, Hill slope, and top/bottom plateaus.
    3. Quality metrics: Require R^2 > 0.95 and Hill slope between 0.5 and 2.0. Steep Hill slopes (> 2.0) may indicate aggregation or assay artifacts.

    Selectivity profiling

    • Counter-screens: Test against 3-5 closely related family members (e.g., kinase panel for kinase inhibitors).
    • Broader panels: Services like Eurofins SafetyScreen44 or DiscoverX scanMAX profile compounds against hundreds of targets to identify off-target liabilities early.
    • Platform integration: Compare experimental selectivity data against the platform's predicted binding poses across homologous structures to build a computational SAR model.

    Lead optimization cycle

    The design-make-test-analyze loop

    Lead optimization is iterative. Each cycle should take 2-4 weeks:

    1. Design -- Use the platform's de novo design (REINVENT4, GenMol) and docking tools to propose analogs that improve potency, selectivity, or ADMET properties.
    2. Make -- Synthesize 5-15 analogs per cycle. Prioritize changes to one region of the molecule at a time to build clean SAR.
    3. Test -- Run the standard assay cascade: binding, cell activity, solubility, microsomal stability, and permeability (PAMPA or Caco-2).
    4. Analyze -- Feed experimental results back into the platform. Update compound passports with measured data and retrain QSAR models if available.

    Key optimization targets

    PropertyStrategyPlatform tools
    PotencyGrow into sub-pocketsDiffDock
    SelectivityExploit residue differencesSequence alignment, docking
    Metabolic stabilityBlock soft spots (benzylic, phenol)ADMET-AI
    SolubilityAdd polar handles, reduce planarityRDKit descriptors, GraphSol
    PermeabilityReduce MW, HBD count, polar surface areaADMET predictions

    Avoid optimizing a single property in isolation. Improving potency by adding lipophilic groups often worsens solubility and metabolic stability. Track a multi-parameter optimization (MPO) score across every cycle.


    Working with CROs

    Selecting a contract research organization

    CRO typeServicesExample providers
    ChemistryCustom synthesis, medicinal chemistryWuXi, Pharmaron, Evotec
    BiologyAssay development, screeningCharles River, Eurofins
    DMPKIn vitro ADME, PK studiesAbsorption Systems, Sekisui XenoTech
    In vivoEfficacy, toxicologyCovance, Inotiv

    Best practices for CRO engagement

    • Provide clear specifications: Include the platform's synthesis route (AiZynthFinder output), target purity (> 95%), and required quantity (typically 10-50 mg for in vitro, 500 mg+ for in vivo).
    • Request analytical data: Require LCMS, 1H-NMR, and HPLC purity traces for every synthesized compound.
    • Establish compound tracking: Assign platform compound IDs to every CRO-synthesized batch. Register batches in your ELN with links back to the platform project.
    • Milestone-based contracts: Structure CRO agreements around deliverables (number of compounds, assay data packages) rather than time-based billing.

    Regulatory considerations

    Data integrity and traceability

    Regulatory agencies (FDA, EMA) expect full traceability from computational prediction through experimental validation:

    • Audit trail: The platform's job history and _metadata.json exports provide timestamped records of every computation. Archive these alongside experimental data in your regulatory submission dossier.
    • GLP compliance: For IND-enabling toxicology studies, ensure the CRO operates under Good Laboratory Practice. Computational predictions do not require GLP but should be documented in the study report.
    • Electronic records: If your organization follows 21 CFR Part 11, ensure that platform exports stored in your ELN meet electronic signature and audit trail requirements.

    IND-enabling studies

    Before filing an Investigational New Drug (IND) application, the following experimental packages are typically required:

    1. In vitro pharmacology -- Target engagement, potency, selectivity.
    2. In vitro ADME -- Metabolic stability, CYP inhibition/induction, plasma protein binding, permeability.
    3. In vivo PK -- Single-dose pharmacokinetics in at least one rodent and one non-rodent species.
    4. GLP toxicology -- 14-day or 28-day repeat-dose toxicity in two species with toxicokinetics.
    5. Genotoxicity -- Ames test and in vitro micronucleus assay.
    6. CMC -- Chemistry, Manufacturing, and Controls for GMP synthesis.

    The platform's compound passport aggregates predicted ADMET, safety signals from FAERS, and synthesis feasibility data in a single report. This is a useful starting point for IND planning but does not substitute for experimental GLP studies.


    Feedback loop: experimental data back into the platform

    The most valuable part of the wet lab transition is feeding measured data back into computational models:

    • Update compound records: Add experimental IC50, solubility, and PK parameters to platform compound entities. This enriches future passport reports and improves team-wide visibility.
    • Retrain models: If you maintain custom QSAR models, incorporate new experimental data points to improve prediction accuracy for your chemical series.
    • Refine docking models: Compare experimental binding data (SPR KD values) against predicted docking scores. Recalibrate scoring functions or select alternative protein conformations if correlation is poor.
    • Archive and share: Publish finalized datasets (computational + experimental) to platform projects so collaborators can build on validated results rather than re-running predictions.

    Summary timeline

    PhaseDurationKey deliverables
    Hit triage1-2 weeksPrioritized compound list (20-50 compounds)
    Procurement / synthesis2-6 weeksCompounds in hand, QC data
    Primary screen1-2 weeksConfirmed hits (5-15% hit rate typical)
    Dose-response2-3 weeksIC50/EC50 values, selectivity panel
    Lead optimization (per cycle)2-4 weeks5-15 analogs tested per round
    In vivo PK4-6 weeksPlasma exposure, half-life, bioavailability
    IND-enabling6-12 monthsGLP tox, CMC, IND filing

    Was this page helpful?

    Loading...